GSK to build new Singapore r&d facility

Published: 21-Nov-2005

Pharmaceutical company GlaxoSmithKline is to build a new $68m (Euro 34m) research and development facility in Singapore on the same site as the company's existing manufacturing facility. The R&D centre will convert experimental treatments into prescribable medicines when it becomes operational in 2007.


Pharmaceutical company GlaxoSmithKline is to build a new $68m (Euro 34m) research and development facility in Singapore on the same site as the company's existing manufacturing facility. The R&D centre will convert experimental treatments into prescribable medicines when it becomes operational in 2007.

Dr Philip Yeo, chairman of the state-run Agency for Science, Technology and Research, said: 'The new facility will boost Singapore's aim to become a strategic site globally for the production of high-value pharmaceuticals. Singapore now has the strategic manufacturing operations of seven of the world's top pharmaceutical companies. Last year, output from the biomedical sciences cluster reached $16bn, accounting for 9% of total manufacturing output. Singapore aims to increase bio-medical sciences output to US$25bn by 2015,'

In addition to GSK, Merck Sharpe and Dohme, Wyeth, Schering Plough and Pfizer, all have operations in Singapore.

You may also like